|
Post by kc on Jan 20, 2018 21:07:27 GMT -5
This is the age of non-traditional VIRAL marketing. We are old school folks. Our customer focus is under 35 Paradigm shift patients who are not afraid trying something other than shots.
|
|
|
Post by kc on Jan 19, 2018 23:15:31 GMT -5
The bottom right flag is the state of Missouri Show me state
|
|
|
Post by kc on Jan 18, 2018 11:27:08 GMT -5
One buyer could not have bought 10 million shares without disclosure. The offering had to of been purchased by multiple parties or we would’ve seen a filing with the SEC
5% or more requires SEC filing
|
|
|
Post by kc on Jan 18, 2018 8:40:24 GMT -5
Sorry to tell you that the short never dies. The short never goes away. It does not matter if it’s this company or any other company. there are people out there who are going to short the stock. That is what they do.
|
|
|
Post by kc on Jan 17, 2018 21:37:22 GMT -5
Peppy it was not this Toujeo commercial. I don’t think i have ever seen this one before and it was 1:30 so I know that was not the one I saw on Tucker Carlson They one you embedded is a crappy commercial in my view.
|
|
|
Post by kc on Jan 17, 2018 21:11:28 GMT -5
Tresiba is made by Novo Nordisk which is a Danish company. No Frenchies there.
But The Sanofi Toujeo commercial that was on The Fox News channel tonight during Tucker Carlson would fit your “Gotta love the French. The commercial is terrible.”
|
|
|
Post by kc on Jan 17, 2018 21:04:48 GMT -5
Doesn't matter. It is not necessary to define. Let us wait for 9 months to see what will happen. Go ahead to bet on the bankruptcy at that time. If it goes to bankruptcy, I fail with loosing $200K. If not, it is $50Billion business in 3~5 years. Ok, I already lost 200K. Not betting on bankruptcy but to say the "fundamental of the company is solid" is a bit of stretch isn't it? It should be a $50B dollar business I agree.........but it hasn't really gotten started now has it? Many of us have lost big bucks and I know that we all know who we are. Could the company still go bankrupt? Yes of course it can. Will it? I sure hope not as many of us have double or tripled down on our original loses. But Hey its only money. Will MannKind ever be a 50 Billion business. I don’t ever see that happening. Maybe a 5 to 10 billion company in 5 to 10 years. 50 is a big stretch.
|
|
|
Post by kc on Jan 17, 2018 20:59:56 GMT -5
You are correct that most 8-K disclosures have a four-day filing requirement, but I don't think there is an obligation to file anything. When the note was renegotiated the company disclosed that $10 million would be placed in escrow and that Deerfield had an option to take payment in shares in lieu of cash (essentially a call option with a $3.25 strike price). That satisfies the SEC requirement for disclosure on this transaction, and no further disclosure is required until the first quarter 10-Q is filed. That said, many companies will issue an 8-K or PR notice voluntarily even though not required to do so. If there were further negotiations that took place, such as Deerfield accepting a different number of shares than was originally disclosed, then that would trigger a filing obligation because of a material change in the terms. so that means MNKD had to pay them or renegotiate? MNKD has until Friday to tell us if they renegotiated? Peppy then wait for Friday’s scripts that hopefully will be moving upwards but that is not a given since we had several 4 day weeks and that makes data very questionable. The short weeks only helps the Spencer (FOR HIRE) Osborn articles. So lets play this out. Scripts come out Friday AM. Let’s wait until after market close to announce what they did with the 10 Million payment. What ever MannKind does is either good or bad and might as well do it later in the day. Do it after the market closes as it makes the SHORTIES very nervous as to what MannKind is going to do. Mike is a good poker player lets she what cards he holds in his hand.
|
|
|
Post by kc on Jan 17, 2018 17:57:03 GMT -5
|
|
|
Post by kc on Jan 17, 2018 17:48:36 GMT -5
It would have to be Mannkind buying Sanofi for it to read "Mannkind Corporations". That would require a pretty big loan. Didn't you get the memo? If Sanofi, Mannkind Corporation SIf Amgen, Mannkind Corporation AIf Merck, Mannkind Corporation MIf J&J, Mannkind Corporation JIf Apple, Mannkind Corporation AI have been holding this for way too long. Trying to lighten up my (others too!) mood :-) Now I understand you name. ....... tingtongtung
|
|
|
Post by kc on Jan 17, 2018 17:47:37 GMT -5
|
|
|
Post by kc on Jan 17, 2018 17:44:47 GMT -5
Googling suggests that firm is one of the smallest brokerages in the country and has only four offices in Florida. Is presenting there really worth the cost, time, and effort? Read their suggestion about who should attend. I hear that there is some pretty cold weather over most of the country but it is usually pretty nice in Ft. Lauderdale in late Jan. I would attend myself but I don’t think I fit the category of “high net worth individual”, at least not yet. When MNKD gets to $40 I will be. But I bet you could get entry to Mike's presentation if you write to Rose in IR.
|
|
|
Post by kc on Jan 17, 2018 15:59:17 GMT -5
|
|
|
Post by kc on Jan 17, 2018 15:45:33 GMT -5
I like this guy's #4 Pick...
At least one of these biotech stocks should appeal to every investor
By Aaron Levitt, InvestorPlace Contributor
investorplace.com/2018/01/5-big-biotech-stocks-buy-2018/#.Wl-1sSzrt9B
Looking for the archetype “lotto” ticket biotech stock? Then MannKind Corporation (NASDAQ:MKND) is it.
MannKind has just one product — Afrezza. The drug is an inhalable insulin used to treat diabetes. It could be a miracle cure for those suffering from the disease. Things haven’t turned out well for MKND over the years, however.
Prescriptions for the drug continue to come in well under expectations, and revenues from these written prescriptions have been paltry at best. That’s a problem when you are running low on cash and have some pretty decent debts on your balance sheet.
But there have been some positives lately — like a label ruling update from the FDA and the potential for Afrezza to be covered by insurance for some patients. The hope is that these positives, as well as higher scripts, will happen before MannKind runs out of cash. If and when that does, MKND should pop much higher.
At $2.50 per share, MKND stock is really a lotto ticket. But it may be worth it for investors looking for to add some risk to their portfolios.
|
|
|
Post by kc on Jan 17, 2018 15:41:07 GMT -5
Notice trade LULLS on this chart. Why. between 15:33:30 and 15:25:38
Another block 10,000 shares that was not on this chart traded at 15:36:50 It slowed down the time and sales chart too. So there must be imbalances that cause this to happen on the Bid / Ask
Closing Bell block at 16:00:00 was 17,687 shares.
|
|